Stock listing

Munich:DB0 Q32 Bio Inc. Aktie

German listing (Munich) of Q32 Bio Inc. · home listing NASDAQ:QTTB

Follow Q32 Bio Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:QTTB

$8.34 USD -0.19 (-2.2%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:QTTB

Past year +332.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$8.23 – $8.59 USDNov 20, 2026
Volume
476,717 sharesNov 20, 2026
Market cap
$249.6M USDAt the close on Nov 20, 2026 · price × 29.92M shares outstanding
52-week range
$1.93 – $23.57 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$6.66M USDMedian day 506,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Q32 Bio Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:QTTB · Home$8.34 USD-0.19 (-2.2%)476,717$8.36$8.59$8.23$8.53Close on Nov 20, 2026
LSE:0T6G$8.402 USD-0.028 (-0.3%)34$8.16$8.402$8.16$8.43Close on Nov 20, 2026
Frankfurt:DB0€7.535 EUR-0.08 (-1.1%)—€7.20€7.535€7.20€7.615Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:QTTB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$8.34-0.19-2.2%$8.36$8.59$8.23476,717
$8.53-0.10-1.2%$8.585$9.08$8.50261,838
$8.63+0.34+4.1%$8.27$8.73$8.06621,205
$8.29-0.42-4.8%$8.66$8.73$8.251344,084
$8.71-0.11-1.2%$8.83$8.86$8.45243,793
$8.82-0.38-4.1%$9.15$9.15$8.53355,589
$9.20-0.13-1.4%$9.39$9.44$9.13236,085
$9.33-0.01-0.1%$9.21$9.74$9.21324,308
$9.34+0.09+1.0%$9.35$9.65$9.01413,223
$9.25+0.40+4.5%$8.83$9.34$8.83214,625
$8.85-0.12-1.3%$8.91$8.93$8.23583,246
$8.97+0.21+2.4%$8.865$9.17$8.52215,502
$8.76+0.05+0.6%$8.68$9.035$8.68175,200
$8.71-0.20-2.2%$8.89$9.00$8.545246,692
$8.91+0.04+0.5%$8.87$8.98$8.53268,080
$8.87-0.19-2.1%$9.20$9.349$8.86317,788
$9.06+0.35+4.0%$8.65$9.11$8.51409,200
$8.71+0.26+3.1%$8.52$8.82$8.429692,575
$8.45-0.20-2.3%$8.60$8.825$8.39563,686
$8.65-0.15-1.7%$8.80$8.835$8.30404,000
$8.80+0.13+1.5%$8.67$9.01$8.60363,600
$8.67+0.05+0.6%$8.62$8.81$8.55322,100
$8.62+0.83+10.7%$7.79$8.84$7.79506,100
$7.79+0.27+3.6%$7.52$7.94$7.52609,900
$7.52-0.25-3.2%$7.82$7.82$7.28678,000
$7.77-0.24-3.0%$8.01$8.29$7.72625,300
$8.01-0.05-0.6%$7.93$8.30$7.72889,300
$8.06-0.68-7.8%$8.69$8.69$7.89719,800
$8.74+0.40+4.8%$8.64$9.155$8.44682,300
$8.34+0.25+3.1%$8.125$8.46$7.94854,600
$8.09+0.10+1.3%$7.94$8.12$7.62859,600
$7.99-0.12-1.5%$8.00$8.07$7.83569,600
$8.11-0.26-3.1%$8.32$8.36$7.80678,400
$8.37+0.14+1.7%$8.09$8.56$7.81954,800
$8.23-0.02-0.2%$8.35$9.11$8.172,097,000
$8.25-0.02-0.2%$8.36$8.85$7.753,085,900
$8.27-1.26-13.2%$10.40$10.40$7.8785,250,500
$9.53+0.30+3.3%$9.32$9.665$9.164914,800
$9.23+0.46+5.2%$9.21$9.445$8.771,004,900
$8.77-0.45-4.9%$9.20$9.20$8.74514,800
$9.22-0.34-3.6%$9.51$9.55$9.051,075,000
$9.56-1.01-9.6%$10.58$10.58$9.50828,400
$10.57+0.10+1.0%$10.60$10.99$10.53387,200
$10.47-0.07-0.7%$10.57$10.75$10.30359,000
$10.54-0.32-2.9%$10.84$10.97$10.46972,300
$10.86-0.12-1.1%$11.14$11.17$10.69384,000
$10.98-0.19-1.7%$11.17$11.41$10.87504,900
$11.17+0.26+2.4%$10.77$11.29$10.51602,500
$10.91-0.19-1.7%$10.96$11.28$10.63870,600
$11.10+0.38+3.5%$10.82$11.27$10.451,824,300
$10.72-0.42-3.8%$11.00$11.08$10.54937,600
$11.14-0.55-4.7%$11.61$11.95$11.07488,700
$11.69-0.30-2.5%$12.00$12.00$11.57592,900
$11.99-0.81-6.3%$12.60$12.70$11.50851,500
$12.80-0.79-5.8%$13.52$13.59$12.74491,500
$13.59-0.77-5.4%$14.42$14.55$13.35434,600
$14.36-0.51-3.4%$14.77$14.77$14.18331,400
$14.87-0.16-1.1%$14.85$15.32$14.75349,900
$15.03-1.12-6.9%$15.91$16.25$14.92353,400
$16.15-0.03-0.2%$16.08$16.30$15.93203,300
$16.18-0.14-0.9%$16.13$16.52$15.80327,100
$16.32-0.04-0.2%$16.36$16.98$16.06599,089
$16.36+0.39+2.4%$16.50$16.66$15.50691,058
$15.97+0.11+0.7%$15.89$16.29$15.72341,400
$15.86+0.02+0.1%$15.80$16.15$15.51389,100

Splits

1 split · NASDAQ:QTTB · every price before a split is adjusted for it

DayRatioWhat
1-for-18Consolidation
Ticker
Munich:DB0
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Latest news

All Q32 Bio Inc. news

Q32 Bio Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 109 in all · newest Nov 11, 2026 · oldest 2020
Decks
7 decks · latest Sep 30, 2026

Where Q32 Bio Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:QTTB · Home listingNASDAQUnited StatesUSD
gettex:DB0gettexGermanyEUR
Lang & Schwarz:A4ZZ0ZLang & SchwarzGermanyEUR
LSE:0T6GLSEUnited KingdomUSD
BOATS:QTTBBOATSUnited StatesUSD
Dusseldorf:DB0DusseldorfGermanyEUR
Frankfurt:DB0FrankfurtGermanyEUR
Munich:DB0 · This pageMunichGermanyEUR
Stuttgart:DB0StuttgartGermanyEUR
Tradegate:DB0TradegateGermanyEUR

Valuation

P/E 7.7× against a median of 128×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$35.66M USD
P/E
7.7×
EV/sales
−0.7×
EV/EBITDA
−1.9×
Price/book
0.9×
Gross margin
99.5%
Operating margin
34.1%
Net margin
59.8%
Debt to equity
0.0×
Beta vs S&P 500
0.59

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Q32 Bio Inc. · NASDAQ:QTTBUS$249.6M−US$35.66M7.7×−0.7×−1.9×0.9×59.8%0.0×0.59
TransThera Sciences (Nanjing). Inc. · HKEX:2617US$257.1MUS$119.4Mn/an/an/a2.0×n/a0.0×n/a
Eikon Therapeutics, Inc. · NASDAQ:EIKNUS$256.8MUS$44.67Mn/an/an/a0.7×n/a0.7×1.91
SAB Biotherapeutics, Inc. · NASDAQ:SABSUS$255.7MUS$156.5Mn/an/an/a1.2×n/a0.0×1.19
Evommune, Inc. · NYSE:EVMNUS$255.5MUS$86.86Mn/an/an/a1.0×n/a0.0×0.96
Editas Medicine, Inc. · NASDAQ:EDITUS$253.1MUS$119.7Mn/a2.4×n/a3.0×−144.9%0.7×2.22
Turn Therapeutics Inc. · NASDAQ:TTRXUS$247.5MUS$244.2Mn/an/an/a43.5×n/a1.1×1.54
Mabpharm Limited · HKEX:2181US$247.3MUS$279.4M29.7×3.0×28.9×8.5×8.8%1.6×n/a
Lexeo Therapeutics, Inc. · NASDAQ:LXEOUS$245.1MUS$56.52Mn/an/an/a1.1×n/a0.0×1.62
Shandong Boan Biotechnology Company., Limited. Class H · HKEX:6955US$242.7MUS$93.26M227×0.8×4.7×0.6×0.9%0.0×n/a
Curocell, Inc. · KRX:372320US$241.3MUS$192.5Mn/an/an/a4.5×n/a0.2×n/a
Median of the othersUS$250.3MUS$119.6M128×2.4×16.8×1.6×0.9%0.1×1.58

Forecasts

6 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
39.67 USD · Analysts' mean
EPS, year to Dec 2026
-1.39 · 7 analysts
Revenue, year to Dec 2026
333.3K · 6 analysts

Team and board

OfficerRole
Jodie MorrisonChief Executive Officer
Lee KalowskiPRESIDENT & CHIEF FINANCIAL OFFICER
Brendan BurnsSenior Director, Investor Relations and Corporate Communications
David AppuglieseSenior Vice President, Head of People
Ellie HershbergerCHIEF DEVELOPMENT OFFICER
José TrevejoCHIEF MEDICAL OFFICER
Maria MarzilliCHIEF BUSINESS OFFICER
Peter A. MerkelChief of Rheumatology
Shelia VioletteFounder and Chief Scientific Officer

Events

QuarterResultsShare move
Q3 2026Nov 4, 2026 · Before open+2.4%
Q2 2026Aug 5, 2026 · Before open+2.1%
Q1 2026May 5, 2026 · Before open+2.0%
Q4 2025Mar 10, 2026+35.5%
Q3 2025Nov 13, 2025 · Before open−9.1%
Q2 2025Aug 6, 2025 · Before open−1.5%
Q1 2025May 8, 2025 · Before open−1.9%
Q4 2024Mar 11, 2025 · Before open−7.8%
Q3 2024Nov 7, 2024 · Before open−1.1%
Q2 2024Aug 8, 2024 · Before open−10.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+2.0%
Q4 2023Mar 13, 2024 · Before open+1.4%
Q3 2023Nov 14, 2023−14.6%
Q2 2023Aug 14, 2023+2.6%
Q1 2023May 11, 2023+0.2%
Q4 2022Mar 9, 2023−16.9%
Q3 2022Nov 10, 2022+11.1%
Q2 2022Aug 15, 2022+4.7%
Q1 2022May 16, 2022+7.9%
Q4 2021Mar 23, 2022−7.5%

Open Events

Decks

DeckKindSlidesDate
EADV Congress 2026Conference16 slidesSep 30, 2026
Technical Presentation (July 2026)Technical24 slidesJul 13, 2026
American Academy of Dermatology Late Breaker Session 2025Conference16 slidesMar 8, 2025
Investor Presentation (January 2025)Investor deck34 slidesJan 13, 2025
Investor Presentation (December 2024)Investor deck36 slidesDec 11, 2024
Homology Medicines — Merger or Acquisition (January 2024)Merger or acquisition41 slidesJan 26, 2024
Homology Medicines — Merger or Acquisition (November 2023)Merger or acquisition41 slidesNov 16, 2023

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$200M raised · US$18.25 a share · Morgan Stanley +4
Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Cantor (co-lead), Oppenheimer & Co., H.C. Wainwright & Co.
Use of proceeds: With existing cash, fund operations through topline Phase 3 results of the planned registration-directed bempikibart program in severe or very severe AA
Aug 5, 2026
At-the-market programme of common stock
Tranche closed: US$14.2M raised
May 5, 2026
Registered direct offering of common stock and pre-funded warrants
Announced: US$10.5M · US$3.9 a share
Use of proceeds: Working capital, including research, clinical development and commercialization, and advancing bempikibart into future alopecia areata trials
Feb 17, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Homology Medicines, Inc. Priced at US$16.00 a share on Mar 27, 2018.

Price
US$16.00 a share
Shares offered
9,000,000 shares of common stock
Offering size
US$144 million
Underwriters' option
Up to 1,350,000 more shares
Underwriters
BofA Merrill Lynch, Cowen, Evercore ISI, BTIG · In the order on the cover
Shares delivered
On or about Apr 2, 2018

Steps

StepWhen
Draft sent to the SEC in confidenceDec 22, 2017
Filed publiclyMar 2, 2018
Amended 3 timesNewest Mar 27, 2018
Shares registered with an exchangeMar 19, 2018
Declared effective by the SECMar 27, 2018
Final prospectus, with the priceMar 29, 2018

Open IPO · From the cover of the final prospectus (424B4) filed Mar 29, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue53.7M0-6.65M3.21M34.0M2.70M1.67M3.68M
Cost of revenue391.0K487.0K499.0K2.60M9.54M684.2K239.8K
Gross profit53.7M-487.0K-6.65M6.65M24.4M2.70M1.67M5.32M-684.2K-239.8K
Research and development19.2M48.1M31.7M98.4M93.1M100.4M89.4M47.9M21.4M5.69M
Selling, general and administrative17.7M18.0M9.88M10.1M6.76M
Operating income16.9M-66.1M-48.3M-133.3M-95.9M-130.3M-109.9M-59.9M-29.7M-10.0M
Depreciation and amortization391.0K487.0K499.0K1.29M8.35M7.96M6.32M1.29M684.0K239.8K
EBITDA17.3M-65.6M-47.8M-132.0M-87.6M-122.3M-103.6M-58.6M-29.0M-9.76M
Interest expense1.10M1.10M1.50M
Income before tax29.8M-46.1M-87.1M1.20M-95.8M-128.7M-103.9M-55.6M-30.0M-8.05M
Income tax021.0K318.0K715.0K000002
Net income29.8M-47.7M-53.7M-5.00M-95.8M-128.7M-103.9M-55.6M-30.0M-8.05M
Earnings per share, basic2.42-5.12-153.96-0.09-1.73-2.80-2.47-1.95-12.10-3.87
Earnings per share, diluted2.42-6.58-153.96-0.09-1.73-2.80-2.47-1.95-12.10

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents48.3M78.0M25.6M34.0M108.4M217.4M53.8M38.2M51.6M11.4M
Short-term investments00141.0M47.5M0208.6M176.5M78.1M
Receivables555.0K755.0K1.06M909.0K400.0K400.0K800.0K113.3K
Inventory1.75M769.0K1
Current assets55.0M81.9M28.7M181.0M191.9M219.6M266.6M221.7M131.6M12.0M
Property, plant and equipment979.0K1.37M1.78M1.08M2.25M37.0M42.7M35.6M3.15M
Total assets61.8M92.3M47.1M228.5M211.7M263.7M310.6M259.1M137.5M14.2M
Accounts payable879.0K2.99M3.47M1.14M2.37M4.72M2.61M15.7M2.54M893.7K
Current liabilities11.3M16.5M14.1M22.6M17.2M22.7M12.4M22.5M8.86M6.38M
Long-term debt3.47M9.56M43.2M5.07M4.97M
Total debt15.3M18.9M50.8M29.9M23.9M15.4M
Total liabilities19.8M86.7M118.5M50.5M42.1M67.7M52.1M62.7M39.2M6.72M
Shareholders' equity42.0M5.67M-182.9M-130.7M169.7M196.0M258.5M196.4M-39.5M7.50M
Shares outstanding12.9M12.2M359.6K57.5M57.2M50.3M45.1M37.4M2.64M2.08M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-33.5M-67.7M-18.7M-113.7M-109.8M-94.3M-91.4M-42.6M6.48M-8.48M
Capital spending0-75.0K-5.00K-1.28M-2.40M-3.73M-21.8M-24.9M-1.96M-1.99M
Free cash flow-33.5M-67.8M-18.7M-114.9M-112.1M-98.1M-113.2M-67.5M4.52M-10.5M
Cash from investing7.00M19.9M-5.00K36.7M-50.8M204.9M-51.8M-121.8M-81.5M-2.27M
Cash from financing-3.13M95.1M406.0K596.0K52.2M53.1M158.2M151.0M115.2M378.3K
Share buybacks-17.5K
Change in cash-29.7M47.3M5.28M-76.3M-108.4M163.7M15.1M-13.4M40.2M-10.4M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportNov 4, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 28, 2026Big-stake noticeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 14, 2026Insider tradeSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 9, 2026Big-stake noticeSEC
8-K · Current reportSep 30, 2026Current reportSEC
8-K · Current reportSep 14, 2026Current reportSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
4 · Change in ownershipAug 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 5, 2026Quarterly reportSEC
8-K · Current reportAug 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 31, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJul 29, 2026Other filingsSEC
424B3 · ProspectusJul 28, 2026Offer documentSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 21, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 20, 2026Big-stake noticeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
S-3 · Registration statementJul 17, 2026Offer documentSEC
8-K · Current reportJul 15, 2026Material contractSEC
424B5 · ProspectusJul 15, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 14, 2026Other filingsSEC
424B5 · ProspectusJul 13, 2026Offer documentSEC
8-K · Current reportJul 13, 2026Current reportSEC
8-K · Current reportJul 13, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJul 10, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 6, 2026Big-stake noticeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
S-3 · Registration statementJun 25, 2026Offer documentSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
8-K · Current reportJun 16, 2026Meeting outcomeSEC
3 · Initial statement of ownershipJun 8, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJun 4, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 4, 2026Big-stake noticeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 1, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 28, 2026Big-stake noticeSEC
8-K · Current reportMay 27, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K · Current reportApr 24, 2026Current reportSEC
424B5 · ProspectusApr 24, 2026Offer documentSEC
8-K · Current reportMar 27, 2026Material contractSEC
424B5 · ProspectusMar 27, 2026Offer documentSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 12, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 10, 2026Offer documentSEC
10-K · Annual reportMar 10, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 20, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 19, 2026Big-stake noticeSEC
8-K · Current reportFeb 17, 2026Material contractSEC
424B5 · ProspectusFeb 17, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
8-K · Current reportDec 19, 2025Management or board changeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
144 · Notice of proposed saleDec 2, 2025Other filingsSEC
144 · Notice of proposed saleDec 2, 2025Other filingsSEC
8-K · Current reportDec 1, 2025Acquisition or disposalSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
8-K · Current reportOct 21, 2025Current reportSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
4 · Change in ownershipAug 28, 2025Insider tradeSEC
UPLOAD · Letter from the SECAug 28, 2025Other filingsSEC
CORRESP · Letter to the SECAug 26, 2025Other filingsSEC
10-Q · Quarterly reportAug 6, 2025Quarterly reportSEC
8-K · Current reportAug 6, 2025ResultsSEC
CORRESP · Letter to the SECJul 31, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 30, 2025Other filingsSEC
8-K · Current reportJun 25, 2025Management or board changeSEC
8-K · Current reportJun 17, 2025Meeting outcomeSEC
8-K · Current reportMay 23, 2025Current reportSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
8-K · Current reportApr 25, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveApr 22, 2025Other filingsSEC
CORRESP · Letter to the SECApr 17, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 17, 2025Other filingsSEC
UPLOAD · Letter from the SECApr 16, 2025Other filingsSEC
POS AM · Amendment to an effective registrationApr 11, 2025Offer documentSEC
S-3 · Registration statementApr 11, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementApr 11, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 8, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansMar 11, 2025Offer documentSEC
424B3 · ProspectusMar 11, 2025Offer documentSEC
10-K · Annual reportMar 11, 2025Annual reportSEC
8-K · Current reportMar 11, 2025ResultsSEC
424B3 · ProspectusMar 10, 2025Offer documentSEC
8-K · Current reportMar 10, 2025Current reportSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
4 · Change in ownershipFeb 26, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
424B3 · ProspectusFeb 10, 2025Offer documentSEC
8-K · Current reportFeb 10, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
424B3 · ProspectusDec 11, 2024Offer documentSEC
8-K · Current reportDec 11, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 13, 2024Big-stake noticeSEC
424B3 · ProspectusNov 7, 2024Offer documentSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedOct 25, 2024Big-stake noticeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
4 · Change in ownershipSep 30, 2024Insider tradeSEC
4 · Change in ownershipSep 27, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
424B3 · ProspectusAug 8, 2024Offer documentSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
424B3 · ProspectusJul 9, 2024Offer documentSEC
8-K · Current reportJul 9, 2024Current reportSEC
S-8 · Registration statement for employee plansMay 31, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedMay 13, 2024Big-stake noticeSEC
424B3 · ProspectusMay 9, 2024Offer documentSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveApr 30, 2024Other filingsSEC
424B3 · ProspectusApr 29, 2024Offer documentSEC
CORRESP · Letter to the SECApr 25, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 25, 2024Other filingsSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
S-1 · Registration statementApr 19, 2024Offer documentSEC
10-K/A · Annual report, amendedApr 12, 2024Annual reportSEC
SC 13D · Big-stake noticeApr 4, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeApr 1, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeMar 29, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeMar 28, 2024Big-stake noticeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC
4 · Change in ownershipMar 27, 2024Insider tradeSEC

This page holds 200 of 594 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Q32 Bio Inc.’s releases · as of Oct 31, 2026

Common shares
29,923,882
Fully diluted
29,923,882

Fully diluted

LineSharesAs of
Common shares29,923,882Oct 31, 2026

Share count over time

CountShares
Oct 31, 202629,923,882

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Orbimed Advisors LLC4.13MUS$34.1MSep 30, 2026
Atlas Venture Life Science Advisors, LLC2.72MUS$22.5MSep 30, 2026
Boxer Capital Management, LLC2.58MUS$21.3MSep 30, 2026
Bvf Inc2.35MUS$19.4MSep 30, 2026
Ra Capital Management, L.P.2.33MUS$19.3MSep 30, 2026
Bank of America2.2MUS$18.2MSep 30, 2026
T. Rowe Price1.5MUS$12.4MSep 30, 2026
Vanguard1.15MUS$9.48MSep 30, 2026
Opaleye Management Inc.1.12MUS$9.26MSep 30, 2026
JPMorgan1.06MUS$10.1MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
American Century653KUS$5.4MSep 30, 2026
Citadel623KUS$5.16MSep 30, 2026
Baker Bros. Advisors LP548KUS$4.53MSep 30, 2026
Sio Capital Management, LLC529KUS$4.38MSep 30, 2026
Ameriprise500KUS$4.14MSep 30, 2026
Sphera Funds Management LTD.449KUS$3.71MSep 30, 2026
Qube Research & Technologies Ltd381KUS$3.15MSep 30, 2026
Marshall Wace, LLP369KUS$3.05MSep 30, 2026
Point72 Asset Management, L.P.345KUS$2.86MSep 30, 2026
Ikarian Capital, LLC345KUS$2.85MSep 30, 2026
BlackRock340KUS$2.81MSep 30, 2026
abrdn303KUS$2.5MSep 30, 2026
Goldman Sachs289KUS$2.39MSep 30, 2026
Cantor Fitzgerald, L. P.258KUS$2.14MSep 30, 2026
Millennium248KUS$2.05MSep 30, 2026
Sanofi244KUS$2.02MSep 30, 2026
Geode Capital241KUS$1.99MSep 30, 2026
Acorn Capital Advisors, LLC216KUS$1.79MSep 30, 2026
Squarepoint Ops LLC192KUS$1.59MSep 30, 2026
TD190KUS$1.81MSep 30, 2026
Walleye Capital LLC182KUS$1.51MSep 30, 2026
UBS164KUS$1.36MSep 30, 2026
Jane Street161KUS$1.33MSep 30, 2026
Wellington137KUS$1.14MSep 30, 2026
Woodline Partners LP130KUS$1.07MSep 30, 2026
Acadian Asset Management LLC121KUS$998KSep 30, 2026
Velan Capital Investment Management LP120KUS$992KSep 30, 2026
Caption Management, LLC112KUS$927KSep 30, 2026
Dimensional110KUS$912KSep 30, 2026
Manufacturers Life Insurance Company, The108KUS$892KSep 30, 2026
Boothbay Fund Management, LLC106KUS$876KSep 30, 2026
Ghisallo Capital Management LLC100KUS$827KSep 30, 2026
Balyasny Asset Management L.P.99,755US$825KSep 30, 2026
DAFNA Capital Management LLC98,500US$815KSep 30, 2026
Nutshell Asset Management Ltd98,299US$813KSep 30, 2026
First Trust89,134US$737KSep 30, 2026
State Street88,114US$729KSep 30, 2026
Arrowstreet Capital, Limited Partnership75,515US$625KSep 30, 2026
Renaissance Technologies69,800US$577KSep 30, 2026
Susquehanna66,305US$548KSep 30, 2026

This page holds 50 of 103 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund389KUS$4.96MJun 30, 2026
Avantis U.S. Small Cap Value ETF129KUS$1.42MMay 31, 2026
Vanguard Extended Market Index Fund119KUS$1.52MJun 30, 2026
Ultra-Small Company Fund34,613US$441KJun 30, 2026
Fidelity Extended Market Index Fund30,017US$332KMay 31, 2026
iShares Micro-Cap ETF29,465US$375KJun 30, 2026
Fidelity Total Market Index Fund16,801US$186KMay 31, 2026
Fidelity Series Total Market Index Fund15,339US$169KMay 31, 2026
Dimensional U.S. Small Cap ETF14,652US$230KJul 31, 2026
Fidelity Nasdaq Composite Index Fund8,325US$91,991May 31, 2026
All 24 holders
HolderSharesValueAs of
Small-Cap Value Portfolio6,223US$79,281Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund5,934US$75,599Jun 30, 2026
U.S. Micro Cap Portfolio4,890US$76,675Jul 31, 2026
Vanguard Balanced Index Fund4,485US$57,139Jun 30, 2026
Column Small Cap Fund1,976US$21,835May 31, 2026
1290 VT Micro Cap Portfolio1,966US$25,047Jun 30, 2026
Victory Extended Market Index Fund1,087US$17,044Jul 31, 2026
U.S. Targeted Value Portfolio340US$5,331Jul 31, 2026
Avantis U.S. Small Cap Equity ETF314US$3,470May 31, 2026
Total Stock Market Index Trust296US$3,771Jun 30, 2026
U.S. Vector Equity Portfolio101US$1,584Jul 31, 2026
Dimensional VA U.S. Targeted Value Portfolio100US$1,568Jul 31, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND56US$878Jul 31, 2026
Blackstone Alternative Multi-Strategy Fund7US$89Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Kalowski Lee
Officer: CFO and President
Sale1,301USD 8.32US$10,824Oct 6, 2026
Violette Shelia M.
Officer: Chief Scientific Officer
Sale917USD 8.32US$7,629Oct 6, 2026
Morrison Jodie Pope
Director, Officer: CEO
Sale3,221USD 8.32US$26,798Oct 6, 2026
Violette Shelia M.
Officer: Chief Scientific Officer
Sale2,798USD 16.56US$46,335Aug 25, 2026
Morrison Jodie Pope
Director, Officer: CEO
Sale9,845USD 16.56US$163KAug 25, 2026
Kalowski Lee
Officer: CFO and President
Sale3,972USD 16.56US$65,776Aug 25, 2026
OrbiMed Capital GP VII LLC
Director, 10% owner
Buy1,250,000USD 8.00US$10MMay 28, 2026
OrbiMed Capital GP VII LLC
Director, 10% owner
Buy625,000USD 8.00US$5MMay 28, 2026
Xu Diyong
Director, 10% owner
Buy1,250,000USD 8.00US$10MMay 28, 2026
Xu Diyong
Director, 10% owner
Buy625,000USD 8.00US$5MMay 28, 2026

Big stakes

StakeStakeSharesDateFiling
Orbimed Advisors LLC13.90%4.13MJul 16, 2026Schedule 13D
BVF PARTNERS L P/IL9.99%3.04MSep 30, 2026Schedule 13G
Ra Capital Management, L.P.9.90%3.05MSep 30, 2026Schedule 13G
Boxer Capital Management, LLC7.90%2.36MSep 30, 2026Schedule 13G
Bank of America Corp7.40%2.21MSep 30, 2026Schedule 13G
Frazier Life Sciences Public Fund, L.P.5.90%1.76MOct 2, 2026Schedule 13G
T. Rowe Price Associates Inc5.00%1.5MSep 30, 2026Schedule 13G
Atlas Venture Fund X, L.P.3.60%864KMay 26, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Flynn
Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); Oruka Therapeutics, Inc. (Director · Jan 30, 2024 – Jan 30, 2024 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past)
Director · Mar 27, 2018 – Jun 6, 2019 · Past
Mark Iwicki
Other companies: Inhibikase Therapeutics, Inc. (Chief Executive Officer - Inhibikase · Since at least Feb 14, 2025); Third Harmonic Bio Inc. (Director · Since at least Sep 14, 2022); Akero Therapeutics Inc (Director · Since at least Jun 19, 2019); Kala Bio, Inc. (Director · Since at least Jul 19, 2017); Jade Biosciences, Inc. (Director · Apr 2, 2021 – Jun 5, 2024 · Past); Pulmatrix, Inc. (Director · Mar 20, 2017 – Jan 28, 2021 · Past); Aimmune Therapeutics Inc (Director · May 25, 2016 – Oct 10, 2020 · Past)
Director · Since at least Mar 25, 2024
Mary Thistle
Other companies: Aktis Oncology, Inc. (Independent Director · Since at least Jan 8, 2026); Cullinan Therapeutics, Inc. (Chair of the Compensation Committee · Since at least Aug 8, 2024); Vigil Neuroscience Inc (Director · Since at least Apr 18, 2022); Entrada Therapeutics, Inc. (Industry Leader and Independent Director · Since at least Oct 28, 2021); Alaunos Therapeutics, Inc. (Director · Nov 15, 2020 – Jun 6, 2023 · Past); Dimension Therapeutics (Chief Operating Officer · Feb 1, 2017 – Nov 7, 2017 · Past)
Director · Since at least Mar 27, 2018
Steven Gillis
Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Takeda Pharmaceutical Co. Ltd. (Director · Since at least Mar 18, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); Codiak BioSciences Inc (Director · Oct 13, 2020 – Feb 16, 2023 · Past); VBI Vaccines Inc. (Director · Jun 14, 2019 – Jul 27, 2023 · Past); Pulmatrix, Inc. (Director · May 16, 2019 – Aug 28, 2020 · Past)
Director · Jun 6, 2019 – Jun 14, 2023 · Past
Alise Reicin
Other companies: Immatics N.V. (Director · Since at least Mar 18, 2026); Tectonic Therapeutic, Inc. (President and CEO, Director · Since at least Jun 20, 2024); Sana Biotechnology, Inc. (Director · Since at least Feb 3, 2021); Celgene Corporation (PRES., GLOBAL CLINICAL DEV. · Nov 1, 2018 – Nov 20, 2019 · Past)
Director · Jul 11, 2019 – Jun 14, 2023 · Past
Isaac Manke
Other companies: Rainier Acquisition Corporation (Director · Since at least Aug 26, 2026); Addex Therapeutics Ltd (Director · Since at least Mar 18, 2026); OnKure Therapeutics, Inc. (Director · Since at least Oct 4, 2024); Chardan Healthcare Acquisition 2 Corp (Director · Apr 23, 2020 – Apr 23, 2020 · Past)
Director · Since at least Mar 25, 2024
Matthew R Patterson
Other companies: Vor Biopharma Inc. (Director · Feb 4, 2021 – May 22, 2025 · Past); 5 01 Acquisition Corp (Director · Oct 13, 2020 – Oct 16, 2020 · Past); Audentes Therapeutics Inc (Chief Executive Officer, Director · Jul 19, 2016 – Jan 15, 2020 · Past)
Director · Mar 27, 2018 – Jun 14, 2023 · Past
David Grayzel
Other companies: Jade Biosciences, Inc. (Director · Feb 1, 2021 – Jun 5, 2024 · Past); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past)
Director · Since at least Mar 25, 2024
Lee Kalowski
Other companies: Bicycle Therapeutics PLC (President and CFO · May 22, 2019 – Apr 3, 2023 · Past); Eledon Pharmaceuticals, Inc. (Chief Financial Officer · Sep 16, 2014 – Dec 15, 2015 · Past)
PRESIDENT & CHIEF FINANCIAL OFFICER · Since at least Mar 25, 2024
Jason Campagna
Other companies: Intercept Pharmaceuticals Inc (Chief Medical Officer · Dec 1, 2019 – Jan 22, 2021 · Past)
Chief Medical Officer · Mar 25, 2024 – Feb 24, 2025 · Past
All 27 people
PersonSeat
Arthur TzianabosUntil Oct 14, 2026 · Past
Bill LundbergBoard Member · Nov 4, 2026 – Nov 4, 2026 · Past
Brendan BurnsSenior Director, Investor Relations and Corporate Communications · Since at least Nov 4, 2026
Brian KotzinBoard Member · Nov 4, 2026 – Nov 4, 2026 · Past
David AppuglieseSenior Vice President, Head of People · Since at least Nov 4, 2026
Diyong XuDirector · Nov 4, 2026 – Nov 4, 2026 · Past
Ellie HershbergerCHIEF DEVELOPMENT OFFICER · Since at least Sep 14, 2026
Jodie MorrisonChief Executive Officer · Since at least Jul 16, 2026
John P. AtkinsonBoard Member · Nov 4, 2026 – Nov 4, 2026 · Past
José TrevejoCHIEF MEDICAL OFFICER · Since at least Sep 30, 2026
Maria MarzilliCHIEF BUSINESS OFFICER · Since at least Nov 5, 2026
Michael HolersBoard Member · Nov 4, 2026 – Nov 4, 2026 · Past
Michael Lee BlumChief Commercial Officer · Mar 2, 2022 – Feb 23, 2023 · Past
Peter A. MerkelChief of Rheumatology · Since at least Nov 5, 2026
Shelia VioletteFounder and Chief Scientific Officer · Since at least Mar 25, 2024
Simon ReadBoard Member · Nov 4, 2026 – Nov 4, 2026 · Past
Siyamak RastyChief Operating Officer · Mar 27, 2018 – Jul 9, 2019 · Past

Open People

Log in to ask 6ix AI your own questions about Q32 Bio Inc.